257 related articles for article (PubMed ID: 26458424)
1. [Recent progress in leukemic stem cell research for childhood leukemia].
Eguchi M; Eguchi-Ishimae M; Ishii E
Rinsho Ketsueki; 2015 Oct; 56(10):1871-81. PubMed ID: 26458424
[TBL] [Abstract][Full Text] [Related]
2. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
[TBL] [Abstract][Full Text] [Related]
3. [Molecular targeted therapy for leukemic stem cells].
Kikushige Y
Nihon Rinsho; 2015 May; 73(5):811-5. PubMed ID: 25985636
[TBL] [Abstract][Full Text] [Related]
4. [Progress in the leukemic stem cell study and a novel therapeutic approach targeting leukemic stem cells].
Kikushige Y; Miyamoto T; Akashi K
Rinsho Ketsueki; 2017; 58(10):1838-1843. PubMed ID: 28978822
[TBL] [Abstract][Full Text] [Related]
5. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
Kikushige Y; Miyamoto T
Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
[TBL] [Abstract][Full Text] [Related]
7. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
[TBL] [Abstract][Full Text] [Related]
8. [Progress in the studies of acute myelogenous leukemia stem cell].
Cui JW; Zhang XM; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):549-52. PubMed ID: 14575558
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia.
Hwang K; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
Ann Hematol; 2012 Oct; 91(10):1541-6. PubMed ID: 22669506
[TBL] [Abstract][Full Text] [Related]
10. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
[TBL] [Abstract][Full Text] [Related]
11. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Pelosi E; Castelli G; Testa U
Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
[TBL] [Abstract][Full Text] [Related]
12. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity.
She M; Niu X; Chen X; Li J; Zhou M; He Y; Le Y; Guo K
Cancer Lett; 2012 May; 318(2):173-9. PubMed ID: 22198207
[TBL] [Abstract][Full Text] [Related]
13. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
Kikushige Y; Akashi K
Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
[TBL] [Abstract][Full Text] [Related]
14. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.
Shima T; Miyamoto T; Kikushige Y; Yuda J; Tochigi T; Yoshimoto G; Kato K; Takenaka K; Iwasaki H; Mizuno S; Goto N; Akashi K
Exp Hematol; 2014 Nov; 42(11):955-65.e1-5. PubMed ID: 25101977
[TBL] [Abstract][Full Text] [Related]
15. High ALDHdim-expressing CD34+CD38- cells in leukapheresed peripheral blood is a reliable guide for a successful leukemic xenograft model of acute myeloid leukemia.
Lee JY; Park S; Han AR; Lim J; Min WS; Kim HJ
Oncol Rep; 2014 Oct; 32(4):1638-46. PubMed ID: 25069538
[TBL] [Abstract][Full Text] [Related]
16. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
Moshaver B; van Rhenen A; Kelder A; van der Pol M; Terwijn M; Bachas C; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
Stem Cells; 2008 Dec; 26(12):3059-67. PubMed ID: 19096043
[TBL] [Abstract][Full Text] [Related]
17. Leukemic stem cells: identification and clinical application.
Hanekamp D; Cloos J; Schuurhuis GJ
Int J Hematol; 2017 May; 105(5):549-557. PubMed ID: 28357569
[TBL] [Abstract][Full Text] [Related]
18. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.
Marchand T; Pinho S
Front Immunol; 2021; 12():775128. PubMed ID: 34721441
[TBL] [Abstract][Full Text] [Related]
19. Cardiac glycoside ouabain efficiently targets leukemic stem cell apoptotic machinery independent of cell differentiation status.
Poohadsuan J; O'Doherty GA; Owattanapanich W; Kungwankiattichai S; Rojanasakul Y; Issaragrisil S; Luanpitpong S
Cell Commun Signal; 2023 Oct; 21(1):283. PubMed ID: 37828578
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance.
Zhi L; Wang M; Rao Q; Yu F; Mi Y; Wang J
Cancer Lett; 2010 Oct; 296(1):65-73. PubMed ID: 20444543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
